文献速递白血病

达沙替尼联合地西他滨治疗加速期或急变期慢性髓性白血病的I/II期研究

Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.
PubMed 文献 · Am J Hematol · 2020-08-12

该I/II期研究评估达沙替尼联合地西他滨治疗加速期或急变期慢性髓性白血病(CML)的安全性和疗效,共入组30例患者,两种地西他滨剂量方案(10 mg/m2或20 mg/m2每日×10天)联合达沙替尼100 mg每日,目标剂量为达沙替尼140 mg每日。未观察到剂量限制性毒性,28例发生≥3级治疗相关血液学不良事件;13例(48%)达主要血液学缓解,6例(22%)达次要血液学缓解,中位总生存期13.8个月,缓解者总生存期显著优于未缓解者(未达到 vs 4.65个月;P < .001)。作者认为该方案安全有效,需进一步研究。

要点

  • 30例晚期CML患者接受达沙替尼联合地西他滨治疗,未观察到剂量限制性毒性
  • 13例(48%)达主要血液学缓解,6例(22%)达次要血液学缓解
  • 中位总生存期13.8个月,缓解者未达到 vs 未缓解者4.65个月(P < .001)

核心结论

  • 达沙替尼联合地西他滨是治疗晚期CML的安全且有效的方案,需进一步研究。

研究设计与样本

  • I/II期研究,入组30例晚期CML患者,包括7例加速期CML、19例急变期CML和4例费城染色体阳性急性髓系白血病。
  • 研究两种剂量方案:地西他滨10 mg/m2或20 mg/m2每日×10天联合达沙替尼100 mg每日;目标剂量水平为地西他滨10 mg/m2或20 mg/m2每日×10天联合达沙替尼140 mg每日。

主要发现

  • 起始剂量水平下两种方案均未观察到剂量限制性毒性。
  • 28例报告≥3级治疗相关血液学不良事件。
  • 13例(48%)达主要血液学缓解,6例(22%)达次要血液学缓解;这些患者中44%达主要细胞遗传学缓解,33%达主要分子学缓解。
  • 中位总生存期13.8个月,达血液学缓解者总生存期显著高于未缓解者(未达到 vs 4.65个月;P < .001)。

关键数值与推荐

  • 主要血液学缓解率48%(13/30),次要血液学缓解率22%(6/30)。
  • 缓解患者中主要细胞遗传学缓解率44%,主要分子学缓解率33%。
  • 中位总生存期13.8个月;缓解者未达到 vs 未缓解者4.65个月(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of advanced-phase chronic myeloid leukemia (CML) remains unsatisfactory. Single-agent tyrosine kinase inhibitors have modest and short-lived activity in this setting. We conducted a phase I/II study to determine safety and efficacy of the combination of dasatinib and decitabine in patients with advanced CML. Two different dose schedules were investigated with a starting decitabine dose of either 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 100 mg daily. The target dose level was decitabine 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 140 mg daily. Thirty patients were enrolled, including seven with accelerated-phase CML, 19 with blast-phase CML, and four with Philadelphia-chromosome positive acute myeloid leukemia. No dose-limiting toxicity was observed at the starting dose level with either schedule. Grade ≥3 treatment emergent hematological adverse events were reported in 28 patients. Thirteen patients (48%) achieved a major hematologic response and six (22%) achieved a minor hematologic response, with 44% of these patients achieving a major cytogenetic response and 33% achieving a major molecular response. Median overall survival (OS) was 13.8 months, with significantly higher OS among patients who achieved a hematologic response compared to non-responders (not reached vs 4.65 months; P < .001). Decitabine plus dasatinib is a safe and active regimen in advanced CML. Further studies using this combination are warranted.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Abaza Y, Kantarjian H, Alwash Y, et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020. PMID: 32681739. doi:10.1002/ajh.25939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。